Results 11 to 20 of about 112,374 (313)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction

ESC Heart Failure, 2023
Aims This study aimed to investigate the prognostic value of dynamic changes in left ventricular ejection fraction (EF) for cardiovascular (CV) outcomes in an all‐comer heart failure (HF) population with reduced EF (HFrEF, EF 4 vs.
Dan Liu, Kai Hu, Lena Schregelmann, Clara Hammel, Björn Daniel Lengenfelder, Georg Ertl, Stefan Frantz, Peter Nordbeck   +7 more
doaj   +3 more sources

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Evidence suggests differences in clinical characteristics, causes, and prognoses between heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Tin‐Kwang Lin, Bo‐Cheng Hsu, Yi‐Da Li, Chi‐Hsien Chen, Jiunn‐Wen Lin, Chen‐Yu Chien, Chia‐Ying Weng   +6 more
doaj   +4 more sources

Vericiguat for Heart Failure with Reduced Ejection Fraction [PDF]

Current Cardiology Reports, 2021
AbstractPurpose of ReviewThe nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway plays an important role in the regulation of cardiovascular function, and it is disrupted in heart failure (HF), resulting in decreased protection against myocardial injury.
Lombardi C. M., Cimino G., Pagnesi M., Dell'Aquila A., Tomasoni D., Ravera A., Inciardi R., Carubelli V., Vizzardi E., Nodari S., Emdin M., Aimo A.   +11 more
openaire   +4 more sources

Advanced heart failure with reduced ejection fraction [PDF]

Baylor University Medical Center Proceedings, 2020
Patients suffering advanced heart failure with reduced ejection fraction (HFrEF) account for a large portion of patients admitted to hospitals worldwide. Mortality and 30-day readmission rates for HFrEF are now a focus of value-based payment models, making management of this disease a priority for hospitals, physicians, and payers alike.
Albert Hicks, Jorge F. Velazco, Salman Gohar, Ahmed Seliem, Shelley A. Hall, Jeffrey B. Michel   +5 more
openaire   +3 more sources

Updates in pharmacotherapy of heart failure with reduced ejection fraction [PDF]

Annals of Translational Medicine, 2021
Heart failure is a common entity encountered in healthcare with a vast socioeconomic impact. Recent advances in pharmacotherapy have led to the development of novel therapies with mortality benefits, improvement in heart failure symptoms and hospitalizations.
Haider Alkhateeb, Tariq Siddiqui, Clifton Espinoza   +2 more
openaire   +2 more sources

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [PDF]

New England Journal of Medicine, 2019
In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the
Mikhail Kosiborod, Silvio E. Inzucchi, Scott D. Solomon, Mikaela Sjöstrand, Morten Schou, Kieran F. Docherty, Jonathan G. Howlett, Jonathan G. Howlett, Chern-En Chiang, Chern-En Chiang, Vijay K. Chopra, Jose C. Nicolau, Olof Bengtsson, Andrej Dukát, Felipe Martinez, Marc S. Sabatine, Marc S. Sabatine, Junbo Ge, Jarosław Drożdż, Tereshchenko Sn, Tzvetana Katova, Béla Merkely, Piotr Ponikowski, AM Langkilde, Pham Nguyen Vinh, Michael Böhm, Jan Bělohlávek, Lars Køber, David L. DeMets, John J.V. McMurray, Eileen O'Meara, Claes Held, Akshay S. Desai, Rudolf A. de Boer, Mark C. Petrie, Masafumi Kitakaze, Pardeep S. Jhund, Subodh Verma, Charlotta Ljungman, Mirta Diez, Inder S. Anand   +40 more
openaire   +14 more sources

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine, 2020
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure ...
Armstrong, Paul W, Pieske, Burkert, Anstrom, Kevin J, Ezekowitz, Justin, Hernandez, Adrian F, Butler, Javed, Lam, Carolyn S P, Ponikowski, Piotr, Voors, Adriaan A, Jia, Gang, McNulty, Steven E, Patel, Mahesh J, Roessig, Lothar, Koglin, Joerg, O'Connor, Christopher M, Nodari S   +16 more
openaire   +9 more sources

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
The findings of randomized trials of neurohormonal modulation have been neutral in heart failure with preserved ejection fraction and consistently positive in heart failure with reduced ejection.
Rohan Samson, Thierry H. Le Jemtel
doaj   +1 more source

Chronic heart failure with reduced ejection fraction [PDF]

Canadian Medical Association Journal, 2014
See also page [510][1] and [www.cmaj.ca/lookup/doi/10.1503/cmaj.131742][2] Heart failure with reduced ejection fraction is a clinical syndrome of dyspnea, exercise intolerance and/or edema resulting from an impairment of ejection of blood, usually documented by a left ventricular ejection ...
Yasbanoo Moayedi, Jeremy Kobulnik
openaire   +3 more sources

Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines

ESC Heart Failure, 2020
Currently, the assessment of left ventricular ejection fraction (LVEF) is the cornerstone of the classification of patients with heart failure (HF). The mid‐range LVEF (HFmrEF) category was identified in an attempt to uncover specific characteristics of ...
Luca Branca, Marco Sbolli, Marco Metra, Marat Fudim   +3 more
doaj   +1 more source